CAI Dongchen (Chairman)
Mr. Cai is the Chairman of the Board and an Executive Director of the Company. He has served as an Executive Director of the Company since April 1997. Mr. Cai is also the Chairman of the Nomination Committee and a director of certain subsidiaries of the Company.

Mr. Cai holds an MBA from Nankai University and has extensive technical and management experience in the pharmaceutical industry.

Mr. Cai is the father of Dr. Cai Lei, the Vice-Chairman of the Board, an Executive Director and the Chief Executive Officer of the Company, and Mr. Cai Xin, an Executive Director of the Company.

Mr. Cai is a substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”). He is also a director of True Ally Holdings Limited and Massive Giant Group Limited, both being substantial shareholders of the Company within the meaning of Part XV of the SFO.

CAI Lei (Vice-Chairman and Chief Executive Officer)
Dr. Cai is the Vice Chairman of the Board, an Executive Director and the Chief Executive Officer of the Company. He has served as an Executive Director of the Company since December 2025.

Dr. Cai is the son of Mr. CAI Dong Chen, the Chairman of the Board, an Executive Director and a substantial shareholder of the Company within the meaning of Part XV of the SFO, and the elder brother of Mr. CAI Xin, an Executive Director of the Company.

Dr. Cai holds a Bachelor’s degree in Biochemistry from Beijing Normal University and a Doctoral degree from the National University of Singapore.

WEI Qingjie (Vice-Chairman and Chief Operating Officer)
Mr. Wei is the Vice Chairman of the Board, an Executive Director and the Chief Operating Officer of the Company. He has served as an Executive Director of the Company since December 2025.

Mr. Wei previously held the positions of Director and Deputy General Manager of North China Pharmaceutical Company Limited (listed on the Shanghai Stock Exchange, Stock Code: 600812.SH), Deputy General Manager of Sichuan Kelun Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, Stock Code: 002422.SZ), and Non-executive Director and President of Hunan Jingfeng Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, Stock Code: 000908.SZ).

Mr. Wei has over 30 years of technical and management experience in the pharmaceutical industry. He holds a Bachelor’s degree in Medicinal Chemistry from China Pharmaceutical University and is a Professorate Senior Engineer in the Chinese Mainland.

ZHANG Cuilong
Mr. Zhang has served as an Executive Director of the Company since July 2018. He is also an Executive President of the Group and a director of certain subsidiaries of the Company.

Mr. Zhang holds a Bachelor’s degree in Pharmacology from Hebei Medical College (now known as Hebei Medical University) and has extensive technical, marketing and management experience in the pharmaceutical industry.

WANG Zhenguo
Mr. Wang has served as an Executive Director of the Company since January 2012. He is also an Executive President of the Group and a director of certain subsidiaries of the Company.

Mr. Wang holds a Bachelor’s degree in Chemistry from Nankai University and has extensive technical, marketing and management experience in the pharmaceutical industry.

WANG Huaiyu
Mr. Wang has served as an Executive Director of the Company since October 2010. He is also an Executive President of the Group and a director of certain subsidiaries of the Company.

Mr. Wang holds a Bachelor’s degree in Microbiology and Biochemistry from Hebei University and has extensive technical and management experience in the pharmaceutical industry.

LI Chunlei
Dr. Li has served an Executive Director of the Company since December 2017. He is currently the Chief Scientist of the Group in charge of research and development. Dr. Li is also an Executive President of the Group and the General Manager of certain subsidiaries of the Company, a deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and a director of the Hebei Pharmaceutical Engineering Technology Centre.

Dr. Li holds a Bachelor’s degree in Engineering (Biological Pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a Master’s degree in Science (Microbial and Biochemical Pharmaceutics) from Jilin University and a Doctorate in Science (Pharmaceutical Science) from Shenyang Pharmaceutical University.

YAO Bing
Dr. Yao has served as an Executive Director of the Company since May 2024. He is also a Director and General Manager of CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of the Company ( listed on the ChiNext Market of Shenzhen Stock Exchange, Stock Code: 300765.SZ) , and a director of certain subsidiaries of the Company. He has been responsible for the research and development of the Group since 2017.

Dr. Yao holds a Bachelor’s degree in Engineering (Biochemical Engineering), a Master’s degree in Engineering (Biochemical Engineering) and a Doctorate in Engineering (Chemical Engineering and Technology) from Nanjing Tech University, and a Master’s degree in Engineering (Project Management Engineering) from Peking University.

CAI Xin
Mr. Cai has served as an Executive Director of the Company since May 2024. He is also an Executive President of the Group, mainly responsible for the sales business of the Group. Prior to joining the Group, Mr. Cai served as an analyst at CDH Investments.

Mr. Cai is the son of Mr. CAI Dong Chen, the Chairman of the Board, an Executive Director and a substantial shareholder of the Company within the meaning of Part XV of the SFO, and the younger brother of Dr. CAI Lei, the Vice-Chairman of the Board, an Executive Director and the Chief Executive Officer of the Company.

Prior to joining the Group in 2022, Mr. Cai served as an analyst at CDH Investments. Mr. Cai holds a Bachelor’s degree in Science (Pharmacy) from Purdue University and a Master’s degree in Business Administration from the University of New South Wales.

CHEN Weiping
Mr. Chen has served an Executive Director of the Company since December 2024. He is currently an Executive President of the Group. Mr. Chen holds a Bachelor's degree in Engineering (Environmental Engineering) from Hebei University of Science and Technology, and is also a senior engineer and a national registered safety engineer.

QU Zhiyong
Mr. QU has served an Executive Director of the Company since November 2025. He is currently the General Manager of the Group’s Hong Kong Head Office Management Centre and the Group’s Finance Centre, primarily responsible for the financial affairs of the Group. He is also a director of certain subsidiaries of the Company. Mr. QU holds a Bachelor’s degree in Business Administration from the Hefei University of Technology.

Mr. QU is a director of Common Success International Limited, a substantial shareholder of the Company within the meaning of Part XV of the SFO.

WANG Bo
Mr. Wang has served as an Independent Non-executive Director of the Company since December 2012. He is also a member of the Audit Committee, Nomination Committee and Remuneration Committee of the Company.

Mr. Wang is currently the CEO of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd and managing director of Beijing CHNMED Pharmaceutical Consulting Co., Ltd. Mr. Wang graduated from Beijing Institute of Iron and Steel and has extensive experience in pharmaceutical policy research and consulting. Mr. Wang is currently the distinguished researcher of the Research Center of National Drug Policy & Ecosystem.

Mr. Wang is also an Independent Director of Youcare Pharmaceutical Group Co., Ltd. (listed on Shanghai Stock Exchange, Stock Code: 688658.SH).

CHEN Chuan
Mr. Chen has served as an Independent Non-executive Director of the Company since June 2016. He is also a member of the Audit Committee, Nomination Committee and Remuneration Committee of the Company.

Mr. Chen holds a Bachelor’s degree in Medicine from Norman Bethune University of Medical Science and a Master’s degree in Science from Albert Einstein College of Medicine at Yeshiva University.

WANG Hongguang
Prof. Wang has served as an Independent Non-executive Director of the Company since January 2021. He is currently Dean of the Institute of Chinese People’s Life Safety, West China Hospital of Sichuan University, and an adjunct professor of Tianjin University and China Pharmaceutical University.

Prof. Wang is a retired professor of the Institute of Multidisciplinary Biomedical Research of Tsinghua University (National Institute of Biological Sciences, Beijing), and has previously served as a director of the Center of Biotechnology Development of China of the Ministry of Science and Technology and an executive director of Peking University’s China Center for Strategic Studies.

Prof. Wang has long been engaged in the research on technology and economic strategy, and has conducted in-depth research on domestic and foreign biotechnology development and industry policies. He is the founder of “Disparity Economics” and has published 21 books including Bio-economic of China and more than 110 theses. Prof. Wang holds a Bachelor’s degree in Agriculture from Gansu Agricultural University, a Master’s degree in Agriculture and a Doctorate in Agriculture from China Agricultural University.

Prof. Wang is also an Independent Non-executive Director of Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd (listed on The Stock Exchange of Hong Kong Limited, Stock Code: 1349.HK and Shanghai Stock Exchange, Stock Code: 688505.SH).

AU Chun Kwok Alan
Mr. Au, has served an Independent Non-executive Director of the Company since January 2021. He is also the Chairman of the Audit Committee and Remuneration Committee of the Company.

Mr. Au is the founder and managing director of GT Healthcare Group, a private equity platform focusing on cross border healthcare investments. Prior to that, Mr. Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPO and M&A in the region, an executive director at JAFCO Asia Investment Group, responsible for healthcare investments in China, and an investment director of Morningside Group in charge of healthcare investments in Asia.

Mr. Au received a Bachelor’s degree in Psychology from Chinese University of Hong Kong and a Master’s degree in Management from Columbia Business School in New York. Mr. Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA), and an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants.

Mr. Au is also an Independent Director of NovaBridge Biosciences (formerly known as I-Mab Biopharma Co., Ltd. and listed on Nasdaq, Stock Code: NBP).

LAW Cheuk Kin Stephen, JP
Mr. Law has served an Independent Non-executive Director of the Company since March 2021. He is currently the managing director of ANS Capital Limited.

Mr. Law previously served as the finance director and a member of the Executive Directorate of MTR Corporation Limited, the CFO of Guoco Group Limited, Hong Kong and managing director of TPG Growth Capital (Asia) Limited, and held various senior positions in the Morningside Group and Wheelock Group. He is also a member of the board of directors of SOW (Asia) Foundation, the President of the Hong Kong Institute of Certified Public Accountants, a board member of Hong Kong Cyberport Management Company Limited and a member of the Institute of Chartered Accountants in England and Wales.

Mr. Law holds a Bachelor’s degree in Science (Civil Engineering) from the University of Birmingham, the United Kingdom and a Master’s degree in Business Administration from the University of Hull, the United Kingdom.

Mr. Law is a member of the 14th National Committee of the Chinese People’s Political Consultative Conference of the People’s Republic of China. He has also been appointed by the Ministry of Finance of the People’s Republic of China as an expert advisor.

Mr. Law is also an Independent Non-executive Director of China Everbright Limited (listed on The Stock Exchange of Hong Kong Limited, Stock Code:165.HK), Somerley Capital Holdings Limited (listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited, Stock Code: 8439.HK), China Galaxy Securities Co., Ltd., (listed on The Stock Exchange of Hong Kong Limited, Stock Code: 6881.HK), Keymed Biosciences Inc. (listed on The Stock Exchange of Hong Kong Limited, Stock Code: 2162.HK) and XtalPi Holdings Limited (listed on The Stock Exchange of Hong Kong Limited, Stock Code: 2228.HK).

Li Quan
Ms. Li has served an Independent Non-executive Director of the Company since November 2022. She is also a member of the Nomination Committee of the Company.

Ms. Li has over ten years of experience in investment management. She is currently the Operating Partner of CDH Investments Management (Hong Kong) Limited.

Ms. Li holds a Bachelor of Cell Biology & Genetics and Economics double degree from Peking University, and a Master of Science degree from National University of Singapore School of Computing.